Tech Center 1600 • Art Units: 1624
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18054527 | Small Molecule Inhibitors Targeting the Sodium Channel Tamoxifen Receptor and Uses Thereof | Non-Final OA | Northwestern University |
| 17425119 | METHODS OF CONTROLLING OR PREVENTING INFESTATION OF CORN PLANTS BY PHYTOPATHOGENIC MICROORGANISMS | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 19237500 | IMPROVED MIRDAMETINIB TREATMENT | Final Rejection | SpringWorks Therapeutics, Inc. |
| 17934553 | 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 17605956 | 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17265333 | ADJUVANT EFFECT OF THE TLR1/2 AGONIST DIPROVOCIM SYNERGIZES WITH CHECKPOINT-INHIBITING ANTIBODIES TO ELIMINATE DISEASE | Final Rejection | The Board of Regents of the University of Texas System |
| 18274549 | C PRIME AGENTS FOR TREATING METABOLIC DISORDERS | Non-Final OA | The University of Toledo |
| 18258673 | METHODS TO SENSITIZE CANCER CELLS AND STANDARDIZED SCREENING ASSAY FOR IMMUNOTHERAPY | Non-Final OA | THE TRUSTEES OF INDIANA UNIVERSITY |
| 18547038 | SMARCA DEGRADERS AND USES THEREOF | Non-Final OA | Kymera Therapeutics, Inc. |
| 17600660 | GEPOTIDACIN FOR USE IN THE TREATMENT OF BACTERIAL URINARY TRACT INFECTIONS | Non-Final OA | GlaxoSmithKline Intellectual Property Development Limited |
| 18262155 | PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER | Non-Final OA | Lupin Limited |
| 18481566 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE | Non-Final OA | Boehringer Ingelheim Vetmedica GmbH |
| 18199776 | INHIBITION OF HIV INFECTION THROUGH CHEMOPROPHYLAXIS | Non-Final OA | THE U.S.A., as represented by the Secretary, Department of Health and Human Services |
| 18249774 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | Non-Final OA | Arena Pharmaceuticals, Inc. |
| 18546217 | SMALL MOLECULE ACTIVATORS OF YAP TRANSCRIPTIONAL ACTIVITY FOR REGENERATIVE ORGAN REPAIR | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 18349256 | TREATMENT OF BRAIN METASTASES AND CNS METASTASES USING ILLUDINS OR HYDROXYLUREAMETHYL ACYLFULVENE | Non-Final OA | Lantern Pharma Inc. |
| 18126273 | METHOD FOR TREATING DEMYELINATING CONDITIONS | Final Rejection | GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD. |
| 17268309 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | Final Rejection | TransThera Sciences (Nanjing), Inc. |
| 18271954 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | Non-Final OA | Monte Rosa Therapeutics AG |
| 18281091 | CO-CRYSTAL OF COENZYME QH AND NICOTINAMIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | COCRYSTAL TECHNOLOGY (JIAXING) CO., LTD. |
| 18547018 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | Non-Final OA | Universitat Bielefeld |
| 18007821 | SOLID STATE FORMS OF ENSARTINIB AND ENSARTINIB SALTS | Final Rejection | TEVA PHARMACEUTICALS INTERNATIONAL GMBH |
| 18274864 | BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Non-Final OA | PINOTBIO, INC. |
| 17965754 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Final Rejection | PX ING, LLC |
| 18262821 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Non-Final OA | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. |
| 18356166 | INHIBITORS OF QPCTL AND QPCT | Non-Final OA | 858 Therapeutics, Inc. |
| 18268632 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | Non-Final OA | Newave Pharmaceutical Inc. |
| 18008135 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | Non-Final OA | Buck Institute for Research on Aging |
| 17256034 | A CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES | Final Rejection | Hangzhou DAC Biotech Co., Ltd. |
| 17818951 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | Final Rejection | Orbus Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy